355 related articles for article (PubMed ID: 22938786)
1. Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors.
Ikuma Y; Hochigai H; Kimura H; Nunami N; Kobayashi T; Uchiyama K; Furuta Y; Sakai M; Horiguchi M; Masui Y; Okazaki K; Sato Y; Nakahira H
Bioorg Med Chem; 2012 Oct; 20(19):5864-83. PubMed ID: 22938786
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors: use of a carboxylate prodrug to improve bioavailability.
Ikuma Y; Hochigai H; Kimura H; Nunami N; Kobayashi T; Uchiyama K; Umezome T; Sakurai Y; Sawada N; Tadano J; Sugaru E; Ono M; Hirose Y; Nakahira H
Bioorg Med Chem; 2015 Feb; 23(4):779-90. PubMed ID: 25596166
[TBL] [Abstract][Full Text] [Related]
3. Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554.
Maezaki H; Banno Y; Miyamoto Y; Moritoh Y; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Sasaki M; Tsubotani S; Tani A; Funami M; Yamamoto Y; Tawada M; Aertgeerts K; Yano J; Oi S
Bioorg Med Chem; 2011 Aug; 19(15):4482-98. PubMed ID: 21741847
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel DPP-4 Inhibitors.
Li Q; Zhou M; Han L; Cao Q; Wang X; Zhao L; Zhou J; Zhang H
Chem Biol Drug Des; 2015 Oct; 86(4):849-56. PubMed ID: 25787859
[TBL] [Abstract][Full Text] [Related]
5. Design of potent dipeptidyl peptidase IV (DPP-4) inhibitors by employing a strategy to form a salt bridge with Lys554.
Maezaki H; Tawada M; Yamashita T; Banno Y; Miyamoto Y; Yamamoto Y; Ikedo K; Kosaka T; Tsubotani S; Tani A; Asakawa T; Suzuki N; Oi S
Bioorg Med Chem Lett; 2017 Aug; 27(15):3565-3571. PubMed ID: 28579121
[TBL] [Abstract][Full Text] [Related]
6. The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes.
Deng J; Peng L; Zhang G; Lan X; Li C; Chen F; Zhou Y; Lin Z; Chen L; Dai R; Xu H; Yang L; Zhang X; Hu W
Eur J Med Chem; 2011 Jan; 46(1):71-6. PubMed ID: 21106276
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, biological evaluation, and docking studies of (s)-phenylalanine derivatives with a 2-cyanopyrrolidine moiety as potent dipeptidyl peptidase 4 inhibitors.
Liu Y; Wu Y; Wu H; Tang L; Wu P; Liu T; Hu Y
Chem Biol Drug Des; 2013 Aug; 82(2):140-6. PubMed ID: 23530834
[TBL] [Abstract][Full Text] [Related]
8. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Yoshida T; Akahoshi F; Sakashita H; Kitajima H; Nakamura M; Sonda S; Takeuchi M; Tanaka Y; Ueda N; Sekiguchi S; Ishige T; Shima K; Nabeno M; Abe Y; Anabuki J; Soejima A; Yoshida K; Takashina Y; Ishii S; Kiuchi S; Fukuda S; Tsutsumiuchi R; Kosaka K; Murozono T; Nakamaru Y; Utsumi H; Masutomi N; Kishida H; Miyaguchi I; Hayashi Y
Bioorg Med Chem; 2012 Oct; 20(19):5705-19. PubMed ID: 22959556
[TBL] [Abstract][Full Text] [Related]
9. Discovery of potent dipeptidyl peptidase IV inhibitors through pharmacophore hybridization and hit-to-lead optimization.
Zeng S; Xie H; Zeng LL; Lu X; Zhao X; Zhang GC; Tu ZC; Xu HJ; Yang L; Zhang XQ; Hu W
Bioorg Med Chem; 2013 Apr; 21(7):1749-55. PubMed ID: 23434133
[TBL] [Abstract][Full Text] [Related]
10. Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
Li N; Wang LJ; Jiang B; Li XQ; Guo CL; Guo SJ; Shi DY
Eur J Med Chem; 2018 May; 151():145-157. PubMed ID: 29609120
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, biological screening, and molecular docking studies of piperazine-derived constrained inhibitors of DPP-IV for the treatment of type 2 diabetes.
Kushwaha RN; Srivastava R; Mishra A; Rawat AK; Srivastava AK; Haq W; Katti SB
Chem Biol Drug Des; 2015 Apr; 85(4):439-46. PubMed ID: 25216392
[TBL] [Abstract][Full Text] [Related]
12. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
[TBL] [Abstract][Full Text] [Related]
13. Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: a new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554.
Banno Y; Miyamoto Y; Sasaki M; Oi S; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Tsubotani S; Tani A; Funami M; Tawada M; Yamamoto Y; Aertgeerts K; Yano J; Maezaki H
Bioorg Med Chem; 2011 Aug; 19(16):4953-70. PubMed ID: 21764322
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of novel benzyl-substituted (S)-phenylalanine derivatives as potent dipeptidyl peptidase 4 inhibitors.
Liu Y; Si M; Tang L; Shangguan S; Wu H; Li J; Wu P; Ma X; Liu T; Hu Y
Bioorg Med Chem; 2013 Sep; 21(18):5679-87. PubMed ID: 23938053
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of pyrrolidine-2-carbonitrile and 4-fluoropyrrolidine-2-carbonitrile derivatives as dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.
Wang J; Feng Y; Ji X; Deng G; Leng Y; Liu H
Bioorg Med Chem; 2013 Dec; 21(23):7418-29. PubMed ID: 24153396
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?
Juillerat-Jeanneret L
J Med Chem; 2014 Mar; 57(6):2197-212. PubMed ID: 24099035
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and anti-diabetic activity of triazolotriazine derivatives as dipeptidyl peptidase-4 (DPP-4) inhibitors.
Patel BD; Bhadada SV; Ghate MD
Bioorg Chem; 2017 Jun; 72():345-358. PubMed ID: 28302310
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, structure-activity relationships, and docking studies of 1-(γ-1,2,3-triazol substituted prolyl)-(S)-3,3-difluoropyrrolidines as a novel series of potent and selective dipeptidyl peptidase-4 inhibitors.
Zhang L; Su M; Li J; Ji X; Wang J; Li Z; Li J; Liu H
Chem Biol Drug Des; 2013 Feb; 81(2):198-207. PubMed ID: 22994702
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, evaluation and molecular docking of thiazolopyrimidine derivatives as dipeptidyl peptidase IV inhibitors.
Sharma M; Gupta M; Singh D; Kumar M; Kaur P
Chem Biol Drug Des; 2012 Dec; 80(6):918-28. PubMed ID: 22943413
[TBL] [Abstract][Full Text] [Related]
20. Discovery of β-aminoacyl containing thiazolidine derivatives as potent and selective dipeptidyl peptidase IV inhibitors.
Park WS; Kang SK; Jun MA; Shin MS; Kim KY; Rhee SD; Bae MA; Kim MS; Kim KR; Kang NS; Yoo SE; Lee JO; Song DH; Silinski P; Schneider SE; Ahn JH; Kim SS
Bioorg Med Chem Lett; 2011 Mar; 21(5):1366-70. PubMed ID: 21306895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
